Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
* As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation)
No dose adjustment for DVT / PE patients, based on age, weight or those with mild-to-moderate renal impairment.1 ELIQUIS should be used with caution in patients with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE. ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1
No initial injections or bridging with LMWH required1
ELIQUIS can be taken with or without food1
Missed dose: if a dose is missed, the patient should take ELIQUIS immediately and then continue with twice-daily intake as before1
Liver function testing should be performed prior to initiating ELIQUIS1
Please click here to access the ELIQUIS Patient Information Leaflet.
Reference